CLINICAL EVALUATION INTRAHEPATIC CHOLESTASIS OF PREGNANCY: IMPROVED OBSTETRIC OUTCOMES WITH URSODEOXYCHOLIC ACID THERAPY

Abstract

Aim: Intrahepatic cholestasis of pregnancy (ICP) is a condition that manifests during the second or third trimester as pruritus, with or without jaundice. Although it is a disease that alters maternal well-being, no severe maternal morbidity or mortality is attributed to it. The purpose of this study was to focus on the clinical features of ICP and to determine the influence of ursodeoxycholic acid (UDCA) on the prognosis of pregnancy in terms of symptomatic relief and obstetric outcome. Material-Methods: Forty-seven patients diagnosed with ICP were enrolled in this study. Of these, 35 received cholestyramine (4gr/day) and 12 received UDCA (750 mg/day). The severity of pruritus was graded before treatment and once a week following treatment. Results: UDCA administration significantly improved fetal prognosis and maternal symptoms (p<0,05). Conclusion: Early and accurate detection of ICP is important in order to provide sufficient obstetric surveillance and fetal monitoring. The results of this study suggest that UDCA alters the pathogenesis of the disease and prevents adverse effects on pregnancy.

Keywords

• Intrahepatic Cholestasis
• Pregnancy
• Cholestyramine
• Ursodeoxycholic Acid

GEBELIGIN iINTRAHEPATIK KOLESTAZINDA KLINIK DEGERLENDIRME: URSODEOKSIKOLIK ASID (UDCA) TEDAVISININ GEBELIGIN PROGNOZUNA ETKKiSi

Abstract

Keywords

• intrahepatik Kolestaz
• Gebelik
• Kolesteramin
• Ursodeoksikolik Asid

References

1. 1. Ribalta J, Reyes H, Gonzales MC. S-Adenosyl-LMethionine in the treatment of patient with intrahepatic cholestasis of pregnancy: A randomized, double-blind, placebocontrolled study with negative result. Hepatology 1991; 13:1084-1089. 2. Everson GT. Liver problems in pregnancy: Part 2- managing pre-existing and pregnancy-induced liver disease. Medscape Womens Health 1998; 3(2):2.
2. 3. Brites D, Rodrigues CM, Oliveira N, Cardoso M, Graca LM. Corection of maternal serum bile acid profile during UDCA therapy in cholestasis of pregnancy. J Hepatol 1998; 28:(1):91-98.
3. 4. Meng LJ, Reyes H, Palma J, Hernandez |, Ribalta J, Sjovall J. Effects of UDCA on conjugated bile acids and progesterone metabolized in serum and urine of patients with ICP. J Hepato! 1997; 27(6):1029-1040.
4. 5. Serrano MA, Brites D, Larena MG, Monte MJ, Bravo MP, Oliveira N, Marin JJ. Beneficial effect of UDCA on alterations induced by cholestasis of pregnancy in bile acid ransport across the human placenta. J} Hepatol 1998; 28(5):829- 839.
5. 6. Palma J, Reyes H, Ribalta J, Hernandes |, Sandoval L, Almuna R. UDCA in the treatment of cholestasis of pregnancy: A randomized, double-blind study controlled with placebo. J Hepatol 1997; 27(6):1022-1028.
6. 7. Diaferia A, Nicastri PL, Tartagni M, Loizzi P, lacovizzi C, Di Leo A. UDCA therapy in pregnant women with cholestasis. Int J Gynaecol Obstet 1996; 52(2):133-140.
7. 8. Heikkinen J, Maentausta O, Yléstalo P. Serum bile acid levels in intrahepatic cholestasis of pregnancy during treatment with phenobarbital or cholestyramine . Eur J Obstet Gynecol Reprod Biol 1982; 14:153-162.
8. 9. Brites D, Rodrigues CM, Cardoso M da C, Graca LM. Unusual case of severe cholestasis of pregnancy with early onset, improved by UDCA administration.Eur J} Obstet Gynecol Reprod Biol 1998; 76(2):165-168.